期刊文献+

晚期乳腺癌内分泌治疗现状及展望 被引量:22

原文传递
导出
摘要 乳腺癌属于激素依赖性肿瘤,其内分泌治疗机制是改变激素依赖性肿瘤生长所需要的内分泌微环境,使癌细胞增殖停止于G_O/G_1期,从而达到防控肿瘤和促其缓解的目的。晚期转移性乳腺癌患者由于机体抵抗力弱或者合并其他禁忌证,对二次手术或化疗一般不能耐受;而内分泌治疗由于不良反应小,临床获益率高等优点易于被患者所接受。正是由于这些优势的存在,使内分泌治疗成为晚期乳腺癌治疗措施中的热点,现就晚期乳腺癌内分泌治疗的现状及未来的展望作一综述。
出处 《中华乳腺病杂志(电子版)》 CAS CSCD 2016年第1期54-56,共3页 Chinese Journal of Breast Disease(Electronic Edition)
  • 相关文献

参考文献31

二级参考文献122

  • 1徐兵河.改变乳腺癌临床实践的重要临床试验的回顾与评述[J].中国癌症杂志,2005,15(5):408-412. 被引量:22
  • 2van Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer:the GEPAR-DUO study of the German Breast Group[ J ]. Clin Oncol,2005,23 ( 12 ) :2676 - 2685.
  • 3Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors [ J ]. J Clin Oncol,2006,24(7) : 1037 - 1044.
  • 4Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer[ J ]. Cancer,2007,110( 2 ) :244 - 254.
  • 5Mathew J,Agrawal A,Asgeirsson KS,et al. Primary endocrine therapy in locally advanced breast cancers-the Nottingham experience [ J ]. Breast Cancer Res Treat,2009,113(2) :403 -407.
  • 6Robertson JF, Come SE, Jones SE, et al. Endocrine treatment options for advanced breast cancer--the role of fulvestrant [ J ]. Eur J Cancer,2005,41 ( 3 ) :346 - 356.
  • 7Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastroz, ole, Tamoxifen, or Combined with Tamoxifen (IMPACT)multicenter double-blind randomized trial [ J ]. J Clin Oncol, 2005,23 ( 22 ) : 5108 -5116.
  • 8Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative 'Arimidex' Compared to Tamoxifen (PROACT) trial [ J]. Cancer,2006,106(10) :2095 - 2103.
  • 9Ellis M J, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase Ⅲ randomized trial [ J ]. J Clin Oncol, 2001,19( 18 ) :3805 - 3816.
  • 10Ellis M J, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status [ J ]. Cancer Res, 2003,63 ( 19 ) : 6523 - 6531.

共引文献49

同被引文献163

引证文献22

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部